NewAmsterdam, which reported another phase 3 win in July, plans to use the data to file for approval. However, as happened in ...

Learn about typical dosages of atorvastatin oral tablet for high cholesterol and heart-related risks, including what’s ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein (a) or Lp (a) levels in adults with high risk of cardiovascular events in a ...

People born with inherited high cholesterol — known as the “evil cousin” — may soon have access to new and potentially ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced ... lowering medicines are not approved to lower Lp(a) levels in people living ...

He said this genetic form of high cholesterol affected one in five people and had no approved ... they lower a genetic form of high cholesterol. The Brooklyn trial tested a drug called Obicetrapib ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

New research has found that nearly 137 million adults—or more than half of all U.S. adults—are eligible for semaglutide ...

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.